Article
Allergan Inc. has named Douglas S. Ingram as the company’s new president. Ingram will lead the company’s global commercial operations, with responsibility for its broad portfolio of pharmaceutical, consumer, and medical device products.
Irvine, CA-Allergan Inc. has named Douglas S. Ingram as the company’s new president. Ingram will lead the company’s global commercial operations, with responsibility for its broad portfolio of pharmaceutical, consumer, and medical device products.
With more than 25 years of experience, Ingram has a strong background in the health-care industry, both in the United States and internationally. For the past 3 years, Ingram has served as executive vice president and president for Europe, Africa, and Middle East with Allergan. In this role, he was responsible for its regional pharmaceutical and medical device operations, with a focus on strategic planning, sales and marketing, development, and general management.
Ingram also served as executive vice president and chief administrative officer, and at various times during his career, he led Allergan’s global legal affairs, compliance, internal audit and internal controls, human resources, regulatory affairs and safety, and global corporate affairs and public relations departments.
“During his 17-year tenure at Allergan, Doug has consistently demonstrated leadership and high performance across many segments of our business,” said David E.I. Pyott, chairman of the board and chief executive officer of Allergan. “Doug has built an impressive record of accomplishment and is widely regarded throughout our organization as a leader who is committed to the highest standards of excellence in all areas. I am confident that his broad range of commercial and functional experiences will serve him well as he assumes this new and important role.”
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial